Developing Novel Treatments for Autoimmune Diseases - PATH TO CURES

Page created by Vincent Clarke
 
CONTINUE READING
Developing Novel Treatments for Autoimmune Diseases - PATH TO CURES
A C C E L E R AT E D
                        PAT H T O C U R E S

Developing Novel Treatments for
         Autoimmune Diseases

                          W W W. L A N D O S B I O P H A R M A . C O M
Developing Novel Treatments for Autoimmune Diseases - PATH TO CURES
LANDOS STRENGTHS                                                                                  2

 Scientific, Clinical and                Expandable Oral                                 Financially Stable
 Business Leadership                    Therapeutic Pipeline                        Raised $10M Series A to advance
                                                                                            Lead to Phase 1

                                     TECHNOLOGY
                             First-in-class oral therapeutics with a unique MoA
                                              targeting LANCL2

   Advancing           Product Development                        Validation                      Strong IP
Lead Candidate                                            Strong animal pharmacology      Comp of Matter and Method
                      Successful PreIND for BT-11                                         of Use, Long patent life 2035
 in Crohn’s and                                           in 5 IBD models, toxicology
                         Into the clinic in 2018             and human translation
    Ulcerative                                                                             Possible Exit Strategy
      colitis                                                                                 IPO, M&A or Strategic
                                                                                           Alliance at the end of Ph. 2
Developing Novel Treatments for Autoimmune Diseases - PATH TO CURES
AGENDA                      3

• Unmet Clinical Needs in IBD

• Targeting LANCL2

• Landos Pipeline

• BT-11 Clinical Plan and Data

• Leadership Team

• Financials

• Investment Catalysts
Developing Novel Treatments for Autoimmune Diseases - PATH TO CURES
CROHN’S DISEASE AND ULCERATIVE COLITIS                     4

           IBD afflicts 2 million in the U.S.
           and 5 million people worldwide

         5M afflicted
            $10B         70-90%
                        will require    100,000
           market                       hospitalizations
         25% growth      surgery
Developing Novel Treatments for Autoimmune Diseases - PATH TO CURES
THE IBD MARKET: $10B – 25% GROWTH                                              5

                                                           Immunomodulators
Autoimmune disease           Others
                                                                (19%)
therapeutics market           (5%)
in U.S. is $100 billion

            Biologics
              (68%)
                                                                                5’ASA
                                                                                 (8%)

              Biological treatment dominates most of the market share. However, it is
           expected to drop 11 points, down to 57%, by 2026 due to safety concerns and
               emerging novel technologies with significant competitive advantages
Developing Novel Treatments for Autoimmune Diseases - PATH TO CURES
UNIQUE MOA: LANTHIONINE SYNTHETASE C-LIKE 2                           6

              BT-11                    HOW LANCL2 WORKS
                                       LANCL2 activation by BT-11 intercepts
                                       IBD at two levels: by decreasing the
             LANCL2                    production of inflammatory mediators
                                       (TNF⍺, IFNg, MCP1) and increasing anti-
                                       inflammatory molecules (IL-10, FOXP3) in
                                       the GI tract.
   AC
               cAMP         5’AMP              First in class compounds with oral
                                               ROA and local GI action
                                               BT-11, 48 scaffolds, and 3 billion
       PKA            ATP                      NCEs composition of matter claims
                                               allowed in USPT 9,556,146; 2017 &
                                               9,839,635 in 2018; 15 countries
             Activates IL-10 & FOXP3           Both method of use and
CREB                                           composition of matter claims for
             Inhibits TNF-⍺ & IFN-g            IBD, RA, T1D, T2D, and influenza
Developing Novel Treatments for Autoimmune Diseases - PATH TO CURES
EXPANSIBLE THERAPEUTIC PIPELINE                                                      7

                             Preclinical     Preclinical IND-
 Product       Indication                                         Phase I Phase II
                               POC              enabling
  BT-11           CD                                                    *

  BT-11           UC
  BT-15           T2D
BT-ABA-5a         T2D
   ABA            T2D
    BT-
                  T1D
 12/INT10
 BT-110            Flu
  BT-13            RA

      •    BT-11 will complete CMC and GLP Tox by Q1 2018, file 2 INDs in 2018,
                          and complete Phase I by early 2019.
Developing Novel Treatments for Autoimmune Diseases - PATH TO CURES
BT-11 TARGET PRODUCT PROFILE FOR CD & UC                                                               8

Product Name                                BT-11                               Lead Competitor (TNF-⍺ blockers)

                First: Treatment for alleviation of signs and symptoms and      Treatment to reduce signs and
                induction and maintenance of clinical remission in male and     symptoms and induce and maintain
   Prime        female adult patients with moderate to severe CD.               remission in adult patients with
 Therapeutic                                                                    moderate to severe CD or UC who
 Indications    Second: Treatment for alleviation of signs and symptoms and
                induction and maintenance of clinical remission in male and     have not responded to other
                female adult patients with moderate to severe UC.               therapies.

                Oral once-a-day dosing through a tablet until symptoms          I.V. infusion
ROA/Dosage
                alleviate (8 mg/kg in mouse models)
Formulation     Tablets (Phase 1 & 2)                                           Sterile powder for I.V. infusion

                Activation of the LANCL2 pathway                                Neutralization of TNF-⍺
Mechanism of
             Up-regulation = IL-10, FOXP3
   Action
                Down-regulation = TNF-⍺, IFNg, MCP-1, IL-6
                Efficacy in 5 validated mouse models (8 mg/kg)                  Variable degrees of efficacy in 3
   Efficacy
                                                                                mouse models
   Safety/      Benign safety profile up to 1,000 mg/kg p.o. in dogs and rats   Increased risk for cancer (T cell
 Tolerability   without dose-limiting safety issues.                            lymphoma), infection and death
Developing Novel Treatments for Autoimmune Diseases - PATH TO CURES
EFFICACY OF BT-11 IN 5 VALIDATED MOUSE MODELS OF IBD                              9

       Untreated : Inflamed               BT-11 Treated : Not Inflamed

    Oral BT-11 decreases gut inflammation by 90%, triggers 4x lesion reduction,
        and modulates inflammatory responses by up-regulating IL-10 and
                             down-regulating TNF-a
Developing Novel Treatments for Autoimmune Diseases - PATH TO CURES
BT-11 TARGETS LANCL2 IN THE GI TRACT                                10

                                   Cmax = 28ng/mL
                                      t1/2 = 3.1hr
                                   Kel = -0.225 L/hr
                                    Vd = 3.38 L/kg

                   •   BT-11 systemic absorption is extremely low
                   •   No dose proportionality (80 to 500 mg/kg)
                   •   Limited systemic exposure
                   •   No accumulation in plasma
                   •   Volume of distribution is high
                   •   BT-11 in the colon and colonic contents is high
                   •   90% reduction of inflammation
                   •   BT-11 is stable to stomach and intestinal fluids
ORAL ROUTE OF ADMINISTRATION                                                            11

  In support of it local action in the GI tract, oral and rectal BT-11 administration
    protects from IBD, but I.V. administration of BT-11 fails to protect from IBD.
HUMAN TRANSLATIONAL DATA                                                              12

 Treating human PBMCs from Crohn’s disease patients with increasing concentrations
of BT-11 ex vivo induced IL-10 production and expression of FOXP3 while suppressing
                             production of TNF⍺ and IFNg
BT-11 HAS DEMONSTRATED BENIGN SAFETY PROFILE                                     13

   BT-11 is negative in genotoxicity studies such as the Ames test up to 5,000
                            µg/plate; hERG screening

     Single medium/high dose in rats (0 or 500 mg/kg) 7-day assessment &
            recovery. Multiple Moderate dose in rats (0 or 80 mg/kg)
                        14-day assessment & recovery

         DRF Studies in rats and dogs (0, 250, 500, and 1,000 mg/kg)
           7-day assessment & recovery and safety pharmacology

   28-day tox assessment & recovery in male and female rats (1,000 mg/kg)
   GLP 12-week assessment & 2 week recovery in rats (complete) and dogs
    (ongoing); 9 and 6 month dosing to support continuous dosing of BT-11
                 (post-IND). No dose-limiting safety issues.
BT-11 OUTPERFORMS CURRENT DRUGS AND INDs   14
BT-11 CAN DISRUPT THE IBD Rx PARADIGM                            15

  Our data indicate that BT-11 could be steroid-, biologics-
                 and even surgery-sparing

                     6 MP
    5’ASA       Immunosuppresant                 TNFα blockers

                   BT-11 / LANDOS
                     technology

 Corticosteroids                 α4b7 blockers Surgery

            Current therapies are modestly successful
                   with undesired side effects
GO-TO-MARKET TIMELINE                                           16

2017         2018         2019      2020      2021    2022        2023        2024

    IND          File
  Enabling      INDs    Phase 1    Phase 2a          Phase 2b                 NDA

  Series A              Series B              IPO            Phase 3
   $10M                  $30M
LEADERSHIP TEAM                                                                                            17

  Josep Bassaganya-Riera                             Chris Garabedian
  Chairman and CEO                                   Corporate Advisor
  20 years of business development and               Currently Chairman and CEO of Xontogeny, a company
  fundraising experience in leading biotech          focused on the management of early stage life sciences
  companies with innovative, large-scale             companies from preclinical to clinical proof-of-concept.
  translational programs. Preclinical and clinical   Helped advance a new drug to market when he was the CEO
  expertise in Crohn’s disease and ulcerative        of Sarepta a $4B publicly traded company.
  colitis. Has led large preclinical and clinical
  programs in IBD (>$78M).

                                                     Simon J. Tulloch, MD
  Raquel Hontecillas                                 Senior Clinical Advisor
  Chief Scientific Officer                           25 years of pharmaceutical and biotech experience in
  20 years of translational experience in the        strategic business development, clinical development and
  biotech industry focusing on infectious,           R&D management, both in Europe and the USA. Secured a
  immune-mediated, and metabolic diseases.           $200 million R&D budget and grew the core business from
  Managed an NIH-funded mucosal                      $700 million to $1 billion at Shire Pharmaceuticals; served
  immunology program totaling $57M.                  as CMO of InfaCare, with successful Series A, B, and C fund
                                                     raising. He played a crucial role in NDA and taking Adderall
                                                     to market. He has been involved in filing over 17 INDs and
                                                     several NDAs.
CLINICAL ADVISORY BOARD - IBD                                                                                                        18

  FABIO COMINELLI, MD, PHD                                                        WILLIAM SANDBORN, MD
  Crohn’s Disease Human Clinical Trials                                           Crohn’s Disease Human Clinical Trials
  Director of the UH Case Medical Center.                                         Chief, Division of Gastroenterology and Professor of
  20 years of experience with human clinical                                      Medicine. He has over 20 years of experience with
  trials for new therapeutics in Inflammatory                                     human clinical trials for new Inflammatory Bowel
  Bowel Disease                                                                   Disease (IBD) therapeutics.

  FRANCISCO A. SYLVESTER, MD                                                      JEAN-FREDERIC COLOMBEL, MD
  Pediatric IBD                                                                   Preclinical and Clinical Gastroenterology
  Division Chief for Pediatric Gastroenterology at                                Director of the Helmsley IBD Center at Mount
  UNC Caphel Hill and member of the CCFA                                          Sinai, NYC. 20 years of experience in Crohn’s
  Board of Trustees. Over 25 years of experience                                  disease.    Chair   of     the   International
  in chronic inflammatory diseases.                                               Organization of Inflammatory Bowel Disease
                                                                                  (IOIBD).

                                         DR. MARIA T. ABREU, MD
                                         Preclinical and Clinical Gastroenterology
                                         Faculty of University of Miami Health System.
                                         Over 15 years of experience in IBD, specializing
                                         in mucosa and associated intestinal microbiota
                                         and expertise in precrlinical models and
                                         clinical studies .
FINANCING                                                                             19

         IND-Enabling Studies: $2.5M
                                                         Series A (IND Enabling & Ph. I): $10M
GLP Toxicology Studies, Safety Pharmacology,             Series B Fall 2018 (Ph. 2a, 2b): $30M
Drug ProductFormulation and CMC, IND Filing
                                                                                                 CMC
      Estimated time to file IND: 6 months
                                                                                                 GLP Tox
        Oral Continuous Dosing: $3M                                                              IND filing
                                                                                                 Phase 1
        Human Clinical Studies: $30M                                                             Phase 2a
                                                                                                 Phase 2b
                             Phase 1, 2a, 2b
Estimated time to complete Phase 1: 1 year

                       The FDA has responded positively to the IND-enabling plan and
                           future clinical trials. Pre-IND meeting minutes available.
PHASE 2 EXIT COMPARABLES                                                     20

     Plexxikon: Daiichi Sankyo $835M upfront with $130M in milestones
                           (SMALL MOLECULE)

    Nogra Pharma: Celgene acquired Mongersen (GED0301) for $710M
  upfront with $1.9B in development and sales milestones (ORALLY ACTIVE
                 AND LOCALLY ACTING SMALL MOLECULE)

  Protagonist: J&J commits $990M for an oral Crohn’s drug PTG-200 targets
              IL-23 receptor (ORAL PEPTIDE THERAPEUTIC)

  Theravance: J&J launched a $1B partnership on the pan-JAK inhibitor (TD-
     1473) with $100M cash upfront in a milestone-driven deal (ORALLY
           ACTIVE AND LOCALLY ACTING SMALL MOLECULE)
SUMMARY AND CONCLUSIONS                                                    21

                                  • Landos is uniquely positioned to develop oral,
                                    first-in-class IBD therapeutics, a $10 billion
                   Start Ph. 1      market.
File 2 INDs by   human clinical   • Innovative MoA (LANCL2) with strong IP
    Q2 2018        testing by       protection (NCEs & target).
                    Q2 2018       • Strong animal pharmacology, MoA, toxicology,
                                    and translational data.
  Complete
                                  • Committed leadership with autoimmune disease
  Phase 2a
                  IPO by 2021       and biopharma industry experience ready to
   studies                          execute therapeutic development plans.
   by 2021
                                  • Partnering with Xontogeny for incremental
                                    operational expertise and access to talent.
                                  • Raised $10M Series A from Perceptive Advisors
                                    and seeking $30M for Series B financing.
LANDOS
BIOPHARMA

      JBR@landosbiopharma.com
      www.landosbiopharma.com
                   @LandosBio

       1800 Kraft Drive, Suite 216
           Blacksburg, VA 24060
APPENDIX   23
LANDOS – ACCELERATED PATH TO CURES   24
CURRENT IBD TREATMENT PARADIGM                                25

                                6 MP          TNFα blockers
   5’ASA                   Immunosuppresant

     Severity of disease

Corticosteroids                    α4b7 blockers   Surgery

      Biologics for IBD cost $40,000 to $50,000/patient/year
          Side effects include cancer, infection and death
CMC STUDIES IN THE NEXT 6 MONTHS                                   26

    The CMC profile of BT-11 Drug Substance:
    •   Easy and inexpensive production with low COG
    •   Low solubility and low absorption
    •   Reproducible chemistry with only 4-step synthesis
    •   99% purity even at lab scale
    •   Stable and scalable

    The CMC profile of BT-11 Drug Product:
    •   Current formulation is a tablet
    •   No unusual risks for tablet formulation anticipated
    •   ROA for BT-11 will be oral in humans
    •   Exploring oral modified release formulation
    •   Site-directed release to improve efficacy/dose frequency
Phase 1/1 SAD Study                                                                             27

Phase/Study          Population                Design                 Outcomes               Comments/Purpose
1/1                  Up to 40 normal           Single Ascending       Safety,                Establish maximum
                     healthy volunteers        Dose                   tolerability, PK       tolerated dose (MTD)
Study Type           Phase 1 SAD Clinical Pharmacology Study
Study Title          Single escalating dose study of tolerability and PK of BT-11 oral administration.
Objective            The goal will be to establish the human single dose MTD.
Clinical Endpoints   Primary: To monitor safety and tolerability
                     Secondary: PK profile and local bioavailability in humans
Subjects             Normal healthy volunteers (NHV) aged 18-60, male or female
Study Drugs          Single doses of BT-11 with control tablets administered in 4-5 cohorts of 8
Study Design         Subjects will be randomized to BT-11 (n=6) or placebo (n=2) in 4-5 cohorts of escalating doses.
                     1/100th of NOAEL; 10 mg/kg and increasing twofold until maximum feasible dose (anticipated to
                     be 8 g as a single dose).
Number of subjects   8 NHV in 5 cohorts sequestered for 48 h
Dosing Period        Single dose.
IE Criteria          NHV aged 18-60, male or (functionally sterile) female.
Phase 1/2 MAD Study                                                                            28

Phase/Study          Population               Design                  Outcomes               Comments/Purpose
1/2                  Up to 40 normal          Multiple                Safety,                Establish maximum
                     healthy volunteers       Ascending Dose          tolerability, PK       tolerated dose (MTD)

Study Type           Phase 1 MAD Cinical Pharmacology Study
Study Title          7-d repeat escalating dose study of tolerability and PK of BT-11 oral administration.

Objective            The goal will be to establish the human repeat dose MTD.
Clinical Endpoints   Primary: To monitor safety and tolerability
                     Secondary: PK profile and local bioavailability in humans
Subjects             40 normal healthy volunteers (NHV) aged 18-60, male or female
Study Drugs          7-d dosing of BT-11 or placebo control tablets
Study Design         Subjects will be randomized to BT-11 (n=8) or placebo (n=2) in 4 cohorts of escalating doses.
                     1/100th of NOAEL; 10 mg/kg and increasing twofold until maximum feasible dose (anticipated to
                     be 8 g as a single dose).
Number of subjects   40 NHV (10 NHV in 4 cohorts)

Dosing Period        7-d daily dosing
IE Criteria          NHV aged 18-60, male or (functionally sterile) female.
Power Calculations for BT-11 Clinical Trials                           29

Based on preliminary results from human peripheral blood mononuclear
cells, we estimate a minimum mean difference between vehicle and BT-11 to
be 1.7 with a SD 1.8 for the main endpoint measures. For an alpha = 0.05
and a projected 40% increase in variance, a sample size ≥ 18 will achieve
81% statistical power in a two-tailed test.

Most studies using CDAI use 50 patients per group.
SES-CD has added statistical efficiency to 17-27 patients per group.
Phase 1b UC PK/Biomarker Study                                                                  30

Phase/Study          Population               Design                  Outcomes                Comments/Purpose
1b                   Up to 72 UC              DB, RCT, placebo-       Safety,                 Establish PK and
                     patients                 controlled 12-wk        tolerability, PK        biomarkers in UC

Study Type           Phase 1b UC Study
Study Title          12-wk study of tolerability and PK of BT-11 oral administration.

Objective            The goal will be to establish the PK profile and biomarkers in UC
Clinical Endpoints   Primary: To monitor safety and tolerability
                     Secondary: PK profile, biomarkers, and local bioavailability in humans
Subjects             72 UC patients aged 18-60, male or female
Study Drugs          12-wk dosing of BT-11 low dose (n=18), BT-11 medium dose (n=18), BT-11 high dose (n=18) or
                     placebo tablets (n=18)
Study Design         Subjects will be randomized to BT-11 at 8 mg/kg (n=10) or placebo (n=10), PK at d 1, d7; cytokines
                     (IFN-g, TNF-a, IL-6, IL-10) in PBMC and LPMC, CRP, and fecal calprotectin.
Number of subjects   72 mild to moderate UC patients

Dosing Period        12-wk daily dosing
IE Criteria          Mild to moderate UC patients aged 18-60, male or (functionally sterile) female.
Phase 2 CD Proof-of-Concept (POC) Study                                                          31

Phase/Study          Population               Design                  Outcomes                Comments/Purpose
2                    130 moderate to          DB, RCT placebo-        Clinical remission,     Establish POC efficacy
                     severe CD patients       controlled 12-wk        biomarkers, PK          safety of BT-11 in CD
Study Type           Dose Range Finding Study
Study Title          Phase 2 randomized, double-blind placebo controlled, multicenter study to evaluate the
                     efficacy/safety of oral BT-11 in CD patients with moderate to severe disease.
Objective            To establish POC efficacy and safety of orally administered BT-11 in CD patients.
Clinical Endpoints   Co-Primary Endpoints are clinical remission based on: abdominal pain, stool frequency (PRO2) and
                     50% reduction SES-CD from baseline (endoscopic mucosal healing) at wk 12. Secondary Endpoints
                     are safety, PK modeling, and biomarkers.
Subjects             130 CD patients with moderate to severe disease aged 18-60, male or female
Study Drugs          Oral once-a-day tablet dosing for 12 wk (proposed extension to 48 wk).
Study Design         CD patients will be randomized to oral BT-11 (n=65) or placebo (n=65). Visits at baseline and d 45
                     and 90 to collect blood, feces and endoscopy. Extension to 48 wk of responders.
Number of subjects   130 patients with moderate to severe CD for 90 days.
Dosing Period        90-day daily dosing.
IE Criteria          CD patients with moderate to severe diseases aged 18-60, male or female. SES-CD > 6
Phase 2 UC Proof-of-Concept (POC) Study                                                          32

Phase/Study          Population               Design                  Outcomes                Comments/Purpose
2                    130 moderate to          DB, RCT placebo-        Clinical remission,     Establish POC efficacy
                     severe UC patients       controlled 12-wk        biomarkers, PK          safety of BT-11 in CD
Study Type           Dose Range Finding Study
Study Title          Phase 2 randomized, double-blind placebo controlled, multicenter study to evaluate the
                     efficacy/safety of oral BT-11 in UC patients with moderate to severe disease.
Objective            To establish POC efficacy and safety of orally administered BT-11 in UC patients.
Clinical Endpoints   Co-Primary Endpoints are clinical remission based on: abdominal pain, rectal bleeding, and
                     reduction in MCS to 0-1 (endoscopic mucosal healing) at wk 12. Secondary Endpoints are safety,
                     PK modeling, and biomarkers.
Subjects             130 CD patients with moderate to severe disease aged 18-60, male or female
Study Drugs          Oral once-a-day tablet dosing for 12 wk (proposed extension to 49 wk).
Study Design         UC patients will be randomized to oral BT-11 (n=65) or placebo (n=65). Visits at baseline and d 45
                     and 90 to collect blood, feces and endoscopy. Extension to 48 wk of responders.
Number of subjects   130 patients with moderate to severe UC for 90 days.
Dosing Period        90-day daily dosing.
IE Criteria          UC patients with moderate to severe disease (Mayo Score 6-12) at baseline with endoscopy score
                     >2, disease progression on ASA (Mesalamine failures) aged 18-60, male or female.
BT-11 VERSUS STANDARD-OF-CARE                                              33

         LANCL2-targeting BT-11                 Biologics TNF-⍺ blockers

         BT-11 will have an oral ROA           Limited Efficacy
           BT-11 will have lower COG      VS   Negative safety profile
BT-11 will have a better safety profile        Expensive and IV ROA
BT-11 & LANCL2 PUBLICATIONS                                                     34

                 Carbo A, Gandour RD, Hontecillas R, Philipson N, Uren A, Bassaganya-
                 Riera J.

                 An N,N Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A
                 Novel Lanthionine Synthetase C-Like 2-Based Therapeutic
                 for Inflammatory Bowel Disease.

                 J Med Chem. 2016 Nov 23;59(22):10113-10126. PubMed PMID: 27933891.

                 Activation of LANCL2 by BT-11 Ameliorates IBD by
                 Supporting Regulatory T Cell Stability through
                 Immunometabolic Mechanisms.

                 Inflammatory Bowel Diseases Journal. 2018. In press
BT-11/LANCL2 PUBLICATIONS                                                                                        35

Leber A, Hontecillas R. Zoccoli-Rodriguez V, Bassaganya-Riera J. Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting
Regulatory T Cell Stability through Immunometabolic Mechanisms. Imflammatory Bowel Diseases. 2018 In press.

Carbo A, Gandour RD, Hontecillas R, Philipson N, Uren A, Bassaganya-Riera J. An N,N Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A
Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease. J Med Chem. 2016 Nov 23;59(22):10113-
10126. PubMed PMID: 27933891.

Bissel P, Boes K, Hinckley J, Jortner BS, Magnin-Bissel G, Were SR, Ehrich M, Carbo A, Philipson C, Hontecillas R, Philipson N, Gandour RD,
Bassaganya-Riera J. Exploratory Studies With BT-11: A Proposed Orally Active Therapeutic for Crohn's Disease. Int J Toxicol. 2016
Sep;35(5):521-9. doi: 10.1177/1091581816646356. PubMed PMID: 27230993; PubMed Central PMCID: PMC5033715.

Lu P, Hontecillas R, Philipson CW, Bassaganya-Riera J. Lanthionine synthetase component C-like 2: a new drug target for inflammatory
diseases and diabetes. Curr Drug Targets. 2014 Jun;15(6):565-72. Review. PubMed PMID: 24628287.

Lu P, Hontecillas R, Horne WT, Carbo A, Viladomiu M, Pedragosa M, Bevan DR, Lewis SN, Bassaganya-Riera J. Computational modeling-
based discovery of novel classes of anti-inflammatory drugs that target lanthionine synthetase C-like 2. PLoS One. 2012;7(4):e34643. doi:
10.1371/journal.pone.0034643. PubMed PMID: 22509338; PubMed Central PMCID: PMC3324509.

Bassaganya-Riera J, Guri AJ, Lu P, Climent M, Carbo A, Sobral BW, Horne WT, Lewis SN, Bevan DR, and Hontecillas R. ABA regulated
inflammation via ligand-binding domain-independent activation of PPARg. J. Biol. Chem. 286(4):2505-16.

Lu P, Bevan DR, Lewis SN, Hontecillas R, Bassaganya-Riera J. Molecular modeling of lanthionine synthetase C-like 2: a potential target for
the discovery of novel type 2 diabetes prophylactics and therapeutics. J Mol Model. 2011 Mar;17(3):543-53. doi: 10.1007/s00894-010-
0748-y. PubMed PMID: 20512604.
PATENT LIST   36
You can also read